Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
L Paz‐Ares, D Soulières, I Melezínek… - Journal of cellular …, 2010 - Wiley Online Library
Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
Implications of EGFR PharmDx™ Kit for cetuximab eligibility
C Ensinger, W Sterlacci - Expert review of molecular diagnostics, 2008 - Taylor & Francis
EGF receptor (EGFR) represents an attractive target for anticancer therapies in a variety of
malignant neoplasms, including colorectal, non-small-cell lung, head and neck carcinomas …
malignant neoplasms, including colorectal, non-small-cell lung, head and neck carcinomas …
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer
R Maruyama, H Wataya, T Seto, Y Ichinose - Anticancer research, 2009 - ar.iiarjournals.org
Background: The optimal treatment for patients with progressive non-small cell lung cancer
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
[HTML][HTML] 酪氨酸激酶抑制剂耐药机制及其治疗策略
J QIAO, W CHEN - ncbi.nlm.nih.gov
人类表皮生长因子受体(epidermal growth factor receptor, EGFR) 是原癌基因C-erbB1
的表达产物, 属于酪氨酸激酶生长因子受体家族成员之一, 在人类多种实体肿瘤中过度表达 …
的表达产物, 属于酪氨酸激酶生长因子受体家族成员之一, 在人类多种实体肿瘤中过度表达 …
[HTML][HTML] A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer
K Furukawa, J Ishida, M Inagaki… - Experimental and …, 2012 - spandidos-publications.com
There is no standard treatment and there are no clearly defined guidelines for the treatment
of postoperative recurrent non-small-cell lung cancer (NSCLC). We performed a …
of postoperative recurrent non-small-cell lung cancer (NSCLC). We performed a …
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case
F Shoji, D Kawano, K Ito, Y Morodomi, T Yano… - Surgery today, 2011 - Springer
We report a case of recurrent pulmonary adenocarcinoma, found 2 years after resection,
which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any …
which responded extremely well to erlotinib, after gefitinib treatment had failed to evoke any …
[HTML][HTML] Initial Progression-Free Survival after Non-First Line TKIs Therapy Potentially Guides Immediate Treatment after Its Failure in Advanced Non-Small Cell Lung …
F Wang, G Guo, H Qiu, W He, F Zhou… - Cancer Biology & …, 2012 - ncbi.nlm.nih.gov
Objective The standard therapy after failure of the initial non-first line epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung …
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung …
Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors
Q Jianbing, C Wenping - Zhongguo Fei Ai Za Zhi, 2011 - search.proquest.com
人类表皮生长因子受体 (epiderma l growth factor receptor, EGFR) 是原癌基因 C-erbB1
的表达产物, 属于酪氨酸激酶生长因子受体家族成员之一, 在人类多种实体肿瘤中过度表达 …
的表达产物, 属于酪氨酸激酶生长因子受体家族成员之一, 在人类多种实体肿瘤中过度表达 …